NCT07263061 Time to Post-operative Recovery of Serum Albumin as a Predictor of Outcome in Major Hepato Pancreato Biliary Surgeries
| NCT ID | NCT07263061 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Liver and Biliary Sciences, India |
| Condition | Hepatobiliary Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2025-12-07 |
| Primary Completion | 2026-10-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2025-12-07 with a primary completion date of 2026-10-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hepatobiliary and Pancreatic surgery is associated with substantial risk of postoperative complications. Albumin is a negative acute phase protein. Its rapid decline may be due to degree of inflammation due to surgical procedures. The decline may due to multifactorial causes. Currently, contemporary data regarding the time to recovery of albumin, as a marker for early recovery of patient from surgical stress is sparse. Delta albumin is influenced by perioperative fluid administration and albumin supplementation. Delta albumin may not reflect the true surgical stress. Early post op albumin is a reflection of intraoperative events and not postoperative recovery or events and is unpredictable. Shorter recovery time of albumin is associated with less post op complications and hospital stay. Earlier recovery of albumin predicts lower morbidity and shorter hospital stay.
Eligibility Criteria
Inclusion Criteria: 1. All patients undergoing major Hepato pancreatico Biliary surgeries. 2. Patients who are more than 12 years of age 3. Retrospective arm - Data from 2010 Exclusion Criteria: 1. Patients who refuse or are unable to give consent. 2. Patients with Nephrotic syndrome, Protein losing enteropathies, Inflammatory bowel 3. Disease, Chronic Liver Disease. 4. Emergency Surgeries
Contact & Investigator
Dr Ragini Kilambi, MCh
STUDY DIRECTOR
ILBS
Frequently Asked Questions
Who can join the NCT07263061 clinical trial?
This trial is open to participants of all sexes, aged 13 Years or older, up to 80 Years, studying Hepatobiliary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07263061 currently recruiting?
Yes, NCT07263061 is actively recruiting participants. Contact the research team at prash1108@gmail.com for enrollment information.
Where is the NCT07263061 trial being conducted?
This trial is being conducted at New Delhi, India.
Who is sponsoring the NCT07263061 clinical trial?
NCT07263061 is sponsored by Institute of Liver and Biliary Sciences, India. The principal investigator is Dr Ragini Kilambi, MCh at ILBS. The trial plans to enroll 1,000 participants.